Cargando…

Review on Approved and Inprogress COVID-19 Vaccines

The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Farnudian-Habibi, Amir, Mirjani, Mobina, Montazer, Vahideh, Aliebrahimi, Shima, Katouzian, Iman, Abdolhosseini, Saeed, Rahmani, Ali, Keyvani, Hossein, Ostad, Seyed Nasser, Rad-Malekshahi, Mazda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Brieflands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420219/
https://www.ncbi.nlm.nih.gov/pubmed/36060923
http://dx.doi.org/10.5812/ijpr.124228
_version_ 1784777343814860800
author Farnudian-Habibi, Amir
Mirjani, Mobina
Montazer, Vahideh
Aliebrahimi, Shima
Katouzian, Iman
Abdolhosseini, Saeed
Rahmani, Ali
Keyvani, Hossein
Ostad, Seyed Nasser
Rad-Malekshahi, Mazda
author_facet Farnudian-Habibi, Amir
Mirjani, Mobina
Montazer, Vahideh
Aliebrahimi, Shima
Katouzian, Iman
Abdolhosseini, Saeed
Rahmani, Ali
Keyvani, Hossein
Ostad, Seyed Nasser
Rad-Malekshahi, Mazda
author_sort Farnudian-Habibi, Amir
collection PubMed
description The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted.
format Online
Article
Text
id pubmed-9420219
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Brieflands
record_format MEDLINE/PubMed
spelling pubmed-94202192022-09-02 Review on Approved and Inprogress COVID-19 Vaccines Farnudian-Habibi, Amir Mirjani, Mobina Montazer, Vahideh Aliebrahimi, Shima Katouzian, Iman Abdolhosseini, Saeed Rahmani, Ali Keyvani, Hossein Ostad, Seyed Nasser Rad-Malekshahi, Mazda Iran J Pharm Res Review Article The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted. Brieflands 2022-01-24 /pmc/articles/PMC9420219/ /pubmed/36060923 http://dx.doi.org/10.5812/ijpr.124228 Text en Copyright © 2022, Author(s) https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Review Article
Farnudian-Habibi, Amir
Mirjani, Mobina
Montazer, Vahideh
Aliebrahimi, Shima
Katouzian, Iman
Abdolhosseini, Saeed
Rahmani, Ali
Keyvani, Hossein
Ostad, Seyed Nasser
Rad-Malekshahi, Mazda
Review on Approved and Inprogress COVID-19 Vaccines
title Review on Approved and Inprogress COVID-19 Vaccines
title_full Review on Approved and Inprogress COVID-19 Vaccines
title_fullStr Review on Approved and Inprogress COVID-19 Vaccines
title_full_unstemmed Review on Approved and Inprogress COVID-19 Vaccines
title_short Review on Approved and Inprogress COVID-19 Vaccines
title_sort review on approved and inprogress covid-19 vaccines
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420219/
https://www.ncbi.nlm.nih.gov/pubmed/36060923
http://dx.doi.org/10.5812/ijpr.124228
work_keys_str_mv AT farnudianhabibiamir reviewonapprovedandinprogresscovid19vaccines
AT mirjanimobina reviewonapprovedandinprogresscovid19vaccines
AT montazervahideh reviewonapprovedandinprogresscovid19vaccines
AT aliebrahimishima reviewonapprovedandinprogresscovid19vaccines
AT katouzianiman reviewonapprovedandinprogresscovid19vaccines
AT abdolhosseinisaeed reviewonapprovedandinprogresscovid19vaccines
AT rahmaniali reviewonapprovedandinprogresscovid19vaccines
AT keyvanihossein reviewonapprovedandinprogresscovid19vaccines
AT ostadseyednasser reviewonapprovedandinprogresscovid19vaccines
AT radmalekshahimazda reviewonapprovedandinprogresscovid19vaccines